News

Antibodies Inc. Introduces Next-Gen Guinea Pig RBPMS Antibody

Antibodies Inc. Introduces Next-Gen Guinea Pig RBPMS Antibody

Antibodies Inc. Unveils a Revolutionary Antibody for Retinal Research

Antibodies Inc., a pioneer in providing validated life science research reagents, is thrilled to announce the launch of its new Recombinant Guinea Pig RBPMS Antibody (Clone OTI3B7-GP, Cat. No. 1834-RBPMS). This state-of-the-art antibody is designed specifically for retinal ganglion cell (RGC) research, offering unparalleled performance, specificity, and reproducibility.

The Recombinant Guinea Pig RBPMS Antibody is a proud addition to the PhosphoSolutions brand, which is known for its high-quality neuroscience reagents. This innovation builds upon Antibodies Inc.'s commitment to thorough validation, advanced manufacturing techniques, and an effective global distribution network. The new mAb replaces the previous guinea pig polyclonal RBPMS Antibody (Cat. No. 1832-RBPMS), ensuring researchers benefit from the latest advancements in antibody technology.

Importance of RBPMS in Research

RBPMS, which stands for RNA Binding Protein with Multiple Splicing, has become a gold standard for identifying retinal ganglion cells. By providing accurate cell identification and helping with quantification in studies focused on vision and neurodegeneration, this antibody plays a crucial role in advancing research in these fields. Traditional polyclonal antibodies, while useful, often present challenges such as variability between lots and limited availability.

Advancements with Recombinant Antibody Technology

The Recombinant Guinea Pig RBPMS Antibody (OTI3B7-GP) effectively overcomes these limitations through sophisticated recombinant engineering. This approach removes issues related to lot variability and stock constraints. By integrating a tried and tested antigen-binding region from the OTI3B7 clone with a guinea pig IgG constant region, this antibody promotes efficient multiplexing alongside other antibody types, such as mouse and rabbit antibodies, while maintaining consistent performance over time.

Key advantages of the Recombinant Guinea Pig RBPMS Antibody include:

  • A dedicated antibody for the identification of retinal ganglion cells.
  • A guinea pig format optimized for advanced multiplex immunolabeling techniques.
  • The inclusion of the well-defined OTI3B7-GP clone, featuring a specific amino acid sequence.
  • Production that is animal-free and serum-free, enhancing its ethical profile.
  • High reproducibility between lots, making it ideal for longitudinal studies and multi-site research initiatives.

Validated Applications

This new antibody has undergone rigorous validation for various applications, including immunohistochemistry (IHC) and Western blotting. Researchers can expect clear and specific labeling of retinal ganglion cells in samples from mammals, ensuring their experiments provide reliable and reproducible results, which is vital in high-stakes research.

The introduction of the Recombinant Guinea Pig RBPMS Antibody is a testament to Antibodies Inc.’s ongoing dedication to fostering scientific innovation and exploration through a robust and expanding portfolio of specialized research brands.

Explore More from Antibodies Inc.

For researchers looking into alternative RBPMS antibodies, Antibodies Inc. also offers a Rabbit Polyclonal RBPMS Antibody. For a comprehensive view of their entire offering, researchers are encouraged to delve into the PhosphoSolutions product line provided by Antibodies Inc., which caters to various research needs in neuroscience and related disciplines.

Researchers can now take advantage of the Recombinant Guinea Pig RBPMS Antibody (OTI3B7-GP, 1834-RBPMS), which is readily available through Antibodies Inc. and its authorized distributors across the globe.

About Antibodies Inc.

Antibodies Inc. is dedicated to equipping researchers worldwide with rigorously tested antibodies, recombinant proteins, ELISA kits, and custom services. Through an expanding collection of specialized brands such as PhosphoSolutions, Antibodies Inc. aims to accelerate scientific discovery across fields like neuroscience, cell biology, and translational research.

Frequently Asked Questions

What is the Recombinant Guinea Pig RBPMS Antibody used for?

This antibody is primarily used for identifying retinal ganglion cells in research related to vision and neurodegeneration.

What advantages does the recombinant version have over polyclonal antibodies?

The recombinant version eliminates lot-to-lot variability, ensuring consistency and reliability in experiments.

What applications has the antibody been validated for?

It has been validated for immunohistochemistry (IHC) and Western blotting in mammalian tissue samples.

Is the antibody produced ethically?

Yes, it is produced in an animal-free, serum-free format, adhering to ethical research standards.

Where can I purchase the Recombinant Guinea Pig RBPMS Antibody?

It is available through Antibodies Inc. and their authorized global distributors.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Indico Breach May Expose Thousands to Identity Theft

Updated Category News Views 4

Data Breach Unsettles Indico's Operations Well, this is the kind of headache nobody wants on their spreadsheet—the unpleasant fallout from a significant data breach is rocking Indico Data Solutions. When you hear words like 'unauthorized party' and 'exposed sensitive personal information,' it ought to make investors sit up and pay attention. On May 7, 2026, Indico, the...

Continue Reading
BC Mosaic App Store Unlocks New Tools for Researchers

Updated Category News Views 2

Unleashing Innovation Through Specialized Apps Oh boy, it's about time someone shook things up in the research game. BC Platforms has rolled out the BC Mosaic App Store, a move that's got research types buzzing from Zurich to... well, anywhere healthcare pokes its head. These guys aren't just throwing out some generic, run-of-the-mill tools. No sir, they've created a...

Continue Reading
Qapture Expands Global DeFi Reach with Key Acquisitions

Updated Category News Views 0

Qapture Investments just made a move in the digital finance space that's promising to turn some heads. From acquiring Flammarion Partners to snapping up Hermetik Trading's DeFi strategies, this Bermuda-based investment manager isn't here to play. Led by Frederick Pye, the firm's gearing up for an industry takeover by blending regulation with innovative digital finance...

Continue Reading
stackArmor Secures FedRAMP High: A Strategic Milestone

Updated Category News Views 2

stackArmor: Carving a Niche in Federal Cybersecurity Hey, not every day you wake up to find a company carving its niche in federal cybersecurity quite the way stackArmor is doing. They've recently got their hands on that elusive FedRAMP High authorization for The Armory. What's this mean in English? Well, for starters, these guys are showing they're serious about...

Continue Reading
Power Solutions Litigations Prompt Investor Caution

Updated Category News Views 0

A Storm Brews Over Power Solutions International Look, if you're holding Power Solutions International (NASDAQ:PSIX) in your portfolio, it's time to perk up. The air's thick with talk that Kuehn Law, the firm with a head for shareholder litigation, is on their case. They're poking around, seeing if some executives got a little too creative with the truth. Word on the...

Continue Reading
RMX's QuantrusX™: Transforming Edge Intelligence

Updated Category News Views 1

The Edge Gets Real RMX Industries is tearing up the old rulebook of intelligence with their latest move. They’re calling it Real-World Intelligence, and right off the bat, RMX (OTCQB:RMXI) makes it clear they're not here to sell us some dusty data center illusion anymore. They're putting intelligence where the action is, at the physical edge, and that's something you...

Continue Reading
HIMS Faces Class Action: Investors Eye Leadership

Updated Category News Views 0

Another Day, Another Lawsuit: Hims & Hers in Hot Water Here's the latest conundrum in the corporate world, folks. Hims & Hers Health, Inc. (NYSE: HIMS) is caught up in a class action lawsuit that could shake up the telehealth scene. Investors who found themselves knee-deep in losses during the class period from August 2025 to July 2026 might want to pay attention. The...

Continue Reading
AEC Firms Revamp Strategies Amid Talent Tug-of-War

Updated Category News Views 2

The State of Compensation in AEC Sit back and chew on this—AEC firms are playing a whole new ball game when it comes to compensating their talent. FMI Corporation’s 2026 Compensation Trends Study is putting a spotlight on what really goes on behind the scenes in architecture, engineering, and construction firms. This is about more than just tossing some coin for a...

Continue Reading
Battling Razor Bumps: Breaking a Persistent Cycle

Updated Category News Views 3

Understanding Razor Bumps: More Than a Cosmetic Annoyance Crossing Great Neck this morning, I stumbled across a curious release from Laser by Aleya. Apparently, the problem with those pesky razor bumps plaguing many isn't just skin-deep. For some, especially those with coarse or curly hair, each razor stroke starts a relentless cycle of irritation that's as grinding as...

Continue Reading
iRobot's Roomba Max 875: The Ultimate Cleaning Machine

Updated Category News Views 3

Roomba Max 875 Combo: Setting a New Standard Alright, folks, iRobot's at it again—unleashing what they tout as their beefiest cleaner to date, the Roomba Max 875 Combo Robot. It's a name that might twist your tongue, and this technological titan's feature list is equally complex. You know the routine with these fancy gadget launches: big promises, shiny features, but...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting New Affordable Homes Coming to Sable Run

Updated Category News Views 150

Explore Sable Run: Affordable Living Awaits Century Communities is thrilled to introduce Sable Run, a vibrant new community set to offer accessible homeownership options for families and individuals. With prices beginning in the $300s, Sable Run intends to fulfill the growing demand for modern and affordable housing. Stunning Home Designs This community features two...

Continue Reading
IM Alliance Conference Promises Revolutionary Insights in Healthcare

Updated Category News Views 116

IM Alliance Conference Promises Revolutionary Insights This year, the Independent Medical Alliance (IMA) is preparing to host its 4th Annual Conference with a pivotal theme that speaks volumes about the future of healthcare. Titled "Honest Medicine: Redefining Health," this event will take place from April 4-6 in a bustling setting. With a robust lineup of leading medical...

Continue Reading
Mobile Application Market Surge Driven by AI and Smartphone Trends

Updated Category News Views 259

Transformative Growth in Mobile Application Market The global mobile application market is anticipated to show substantial growth, with a predicted increase of USD 2.63 trillion from 2025 to 2029. The remarkable growth trajectory is attributed to the expanding smartphone penetration and advancements in technology, particularly artificial intelligence (AI) and machine...

Continue Reading
Orezone Gold Fully Exercises Over-Allotment Option for Growth

Updated Category News Views 114

Orezone Gold's Ambitious Expansion Plan Orezone Gold Corporation (TSX: ORE, OTCQX: ORZCF) recently made headlines with its bold move to fully exercise its over-allotment option related to a significant financing deal. By doing so, they secured an additional 6,402,450 common shares at a price of C$0.82 per share, which generated gross proceeds of C$5,250,009. Strategic Use...

Continue Reading
ASP Isotopes Inc. Announces New Public Common Stock Offering

Updated Category News Views 91

ASP Isotopes Inc. Public Offering Announcement In a significant move, ASP Isotopes Inc. (NASDAQ: ASPI) has announced the pricing of its underwritten public offering of common stock. The company plans to sell a total of 2,395,000 shares, priced at $6.75 each. This offering is projected to generate approximately $16.2 million for ASP Isotopes, before accounting for...

Continue Reading